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Abstract
Background: An increasing body of evidence shows that miR-34 family has tumor suppressive properties
mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be
under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is
frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation
of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate
the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special
focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes.
Methods: One hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium
were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR).
Gene-specific DNA methylation was evaluated with MethyLight technique.
Results: Significantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium
(p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers (p = 0.037), in p53 mutated
as compared to p53 wild type cancers (p = 0.003) and in high grade compared to in low grade cancers (p = 0.028).
In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS (p = 0.039) and OS
(p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis (p = 0.022).
miR-34a promoter methylation was found higher in type II cancers than in type I (p = 0.006). mir34a expression and
promoter methylation showed an inverse correlation in cancer samples (p = 0.05).
Conclusion: We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we
corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian
cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor
type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a
in ovarian cancer.
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Background
In epithelial ovarian carcinomas p53 is mutated in more
than 50 % of cases; especially high-grade serous cancer
is one of the most impressive p53 mutation-driven ma-
lignancies with a mutation frequency of more than 95 %
[1]. Based on clinical behaviour, histological characteris-
tics as well as genetic features Kurman et al. [2] pro-
posed a dualistic model to group epithelial ovarian
cancer. Type I cancers arise from borderline tumors and
are often limited to the ovaries at time of diagnosis.
They frequently show mutations of RAS, BRAF and
PTEN. In contrast, type II carcinomas are frequently de-
ficient in the p53 pathway, are more aggressive and thus
often widely spread through the peritoneal cavity at time
of diagnosis [1, 3]. Although first-line treatment is suc-
cessful in most cases, 5-year overall survival (OS) is still
poor which is mainly due to the very high incidence of
early recurrence and the development of platinum resist-
ance during the course of the disease [4].
Micro RNA (miRs) are small non-coding RNAs that ap-
pear to play an important role in cancer development and
their dysregulation is a ubiquitous feature of malignancies
[5]. The miR-34 family is one of the most prominent miR
groups, known to be crucially involved in carcinogenesis
and tumor progression. Members of the miR-34 family
can act either as oncogenes or as tumor-suppressors by
regulating the cell cycle, proliferation, apoptosis, invasion
and metastasis [6]. The tumor-suppressor and transcrip-
tion factor p53 has been shown to directly transactivate
genes of the miR-34 family [7, 8].
Accumulating evidence suggests that many malignan-
cies follow a stem cell model, where a subpopulation of
tumor cells with stem cell properties drives tumor growth,
invasion and metastasis [9]. Because of their relative resist-
ance to conventional therapies, such as chemotherapy or
radiation, these cells may be responsible for treatment re-
sistance and recurrence. A recent work by Liu et al. [10]
showed that miR-34a inhibits expression of the adhesion
molecule CD44 in prostate cancer stem cells, and is able
to block tumor growth and metastasis formation in a
xenograft model. Furthermore, these authors also revealed
that miR-34a reduces the expression of other molecules
crucially involved in the regulation of stem cell pathways
including cyclin D1, cyclin-dependent kinase-4 and −6,
c-myc as well as NOTCH. Altogether, these findings
prompted Max Wicha to highlight the striking role of
miR-34a in the biology of cancer stem cells in one of
his renowned editorial entitled “Stemming a tumor with
a little miR” [11].
The control system of miR-34a seems to be complex, in
fact p53 has been revealed to up-regulate the expression
of miR-34a via direct promotor transactivation [8, 12] but
also miR-34a appeared to be regulated by epigenetic regu-
lation via its specific promoter methylation [13]. The latter
Moreover, proved to be decisive in regulating this miR-
34a-E2F3a axis [12].
All this motivated us to investigate the clinical rele-
vance of miR-34a as well as its promotor methylation
status in a training set of 133 ovarian cancer patients. In
this context particular attention was focused on differ-
ences between type I and type II cancers, p53 mutation-
driven cancers and the various histological subtypes.
Methods
We investigated tissue samples from 133 patients with
invasive, epithelial ovarian cancer. These samples were
collected at the Department of Obstetrics and Gynecology
at the Medical University of Innsbruck during primary
surgery. Tumor specimen were obtained immediately after
surgery and brought to our pathology laboratory, where
the tissue was pulverized under cooling with liquid
nitrogen and stored at −70 °C. Tumors with borderline
malignancy were excluded. Normal ovarian surface
epithelial tissue samples obtained from ovaries removed
for other than inflammatory or tumoral conditions
served as controls (n = 8).
In the present training set of patients the median age
at diagnosis was 62.3 years (Range: 51–71.9). Clinico-
pathological characteristics of the investigated patients
are summarized in Table 1.
RNA extraction, reverse transcription and real-time PCR
analysis
RNA from fresh pulverized, quick-frozen specimens
was extracted as previously described [14]. A TaqMan
microRNA assay specific for miR-34a (Assay ID
000426) was used to detect and quantify mature miR-
34a. miRNA expression was normalized to RNU6B
(Assay ID 001093) using the 2-ΔΔCt method. The as-
says were performed in accordance with manufacturer’s
instructions (Applied Biosystems, Carlsbad, USA) using
an ABI Prism 7900 Detection System. PCR assays were
conducted in triplicate and the mean value was used
for calculation. Values were expressed with TBP: TATA
box-binding protein.
DNA isolation and methylation analyses
Genomic DNA from pulverized, quick-frozen specimens
was isolated using the DNeasy tissue kit (Qiagen, Hilden,
Germany). Bisulfite modification was performed with
the EZ DNA Methylation-Gold Kit (Zymo Research,
Orange, CA, USA) according to the manufacturer’s
instructions. MethyLight analysis was done as described
previously [12]. Primers and probes for miRNA34a were
determined with the computer program Primer Express,
version 2.0.0 (Applied Biosystems, Foster City, CA, USA),
to produce a 111-base-pair PCR amplicon (nucleotide po-
sitions 33.932–34.043 as defined by GenBank accession
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number EF570049; −192 nucleotides to −81 nucleotides
upstream from exon 1). Genomic DNA not treated with
bisulfite (unmodified) was not amplified with the primers
(data not shown).
Primer sequences were: miR-34a Forward 5′-TCCTTC
CTACTCGTACCACCAAA-3′, miR-34a reverse 5′-AGG
TGGAGGAGATGTCGTTGTT-3′, miR-34a Taq Man
probe 5′FAM-CGTCTCTCCAACCCGAAATCCGAAA
AA-3′-BHQ1. CpG islands in the analyzed genes were
identified using a CpG island searcher (http://www.cpgi-
slands.com) which screens for CpG islands that meet the
criteria and algorithm described by Takai and Jones [15].
Values were expressed as PMR value: percentage of
fully methylated reference;
Statistical analysis
Data were expressed as median values and interquartile
ranges. Differences between two and more than two quan-
titative variables were evaluated using respectively Mann
Whitney and Kruskal-Wallis Test. Correlation analyses
were calculated using Spearman rank-correlation test.
Survival analysis for PFS and OS was performed with
the Kaplan-Meier method and statistical differences
were evaluated with log-rank test. Multivariate analysis
(Cox-regression) was performed to determine the
impact of clinical and pathologic factors on survival
outcomes. SPSS, version 22 for Windows, was used for
all analyses.
Results
miR-34a expression and its promotor methylation in
cancer and normal ovarian tissue specimens
From the 133 patients miR-34a expression (miR-34a(EXP))
was available in 95 patients and promotor methylation of
miR-34a (miR-34a(MET)) in 96 patients. For 58 patients
data were available for both variables. The median expres-
sion level of miR-34a was significantly lower in the cancer
specimen than in the healthy control tissue (p = 0.002,
Table 1). No promoter methylation could be measured in
the control tissues. In cancers 61 patients (63.5 %) methy-
lation miR-34a promoter was totally absent presented ab-
sent methylation of and the remaining 35 (36.5 %) had
various levels of methylation (PMR values) ranging from
0.5 to 30.42.
According to the clinico-pathological characteristics
Regarding histo-morphological grading Fig. 1a depicts that
miR-34a(EXP) was revealed to be higher in grade 1 as
Table 1 Clinico-pathological characteristics of the investigated cohort (n = 130)
miR-34a expressiond miR-34a promoter methylation
n. (%) Missing Median p-valueb n. (%) Missing Negative Positive p-valuec
Presence of disease healthy samples 8 5,7 % 0 1,39 8 5,7 % 8 - -
cancers 133 94,3 % 38 0,39 0.002f 133 94,3 % 37 61 34 -
Age <62.3 yearsa 66 49,6 % 16 0,44 66 49,6 % 19 30 17
>62.3 years 67 50,4 % 22 0,33 0.136 67 50,4 % 18 31 17 0.939
Histotype serous 67 50,4 % 22 0,33 67 50,4 % 14 32 21
endometrioid 24 18,0 % 6 0,5 24 18,0 % 6 12 5
mucinous 37 27,8 % 10 0,4 37 27,8 % 15 15 7
clear cell 5 3,8 % 0 1,07 0.215 5 3,8 % 2 2 1 0.799
FIGO stage early stages (I-II) 31 23,3 % 9 0,4 31 23,3 % 10 15 6
late stages (III-IV) 102 76,7 % 29 0,36 0.192 102 76,7 % 27 46 28 0.434
Grading 1 4 3,0 % 1 1,43 4 3,0 % 0 4 0
2 74 55,6 % 23 0,44 74 55,6 % 21 37 15
3 55 41,4 % 14 0,33 0.028e 55 41,4 % 16 20 19 0,046e
Residual disease RD = 0 49 37,1 % 9 0,42 49 37,1 % 19 23 7
RD > 0 83 62,9 % 29 0,36 0.491 83 62,9 % 17 38 27 0,085
Type type 1 91 68,4 % 26 0,43 91 68,4 % 28 45 17
type 2 42 31,6 % 12 0,28 0.037e 42 31,6 % 9 16 17 0,020e
Serous LGSC 13 29,5 % 6 0,77 13 29,5 % 2 8 3
HGSC 31 70,5 % 12 0,21 0.004f 31 70,5 % 7 12 12 0,207
p53 mutation no 30 33,0 % 12 0,7 30 33,0 % 6 18 6
yes 61 67,0 % 19 0,33 0.003f 61 67,0 % 18 22 20 0,07
aMedian value in cancer cohort. bMann–Whitney test or Kruskal-Wallis test cchi-square test. dArbitrary units normalized to TBP. eSignificant at the 0.05 level
(2-tailed). fSignificant at the 0.01 level (2-tailed)
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compared to grade 2 and 3 (p = 0.028, Table 1). Cancers
positive for miR-34a promoter methylation were signifi-
cantly more represented (p = 0.046) in grade 2 and 3 than
in grade 1 (Table 1).
According to the dualistic type I and II model proposed
by Kurman et al. [2] miR-34a(EXP) was significant
lower in type II than in type I cancers (p = 0.037) and
miR-34a(MET) was significantly higher in type II than
in type I (p = 0.020); (Table 1, Fig. 1b). In 36.4 % of the
whole cohort of patients p53 mutation was revealed.
p53 mutated cancers exhibited significantly lower miR-
34a(EXP) than did p53 wild-type cancers (p = 0.003, Fig. 1c).
However, no differences between p53 mutated and
wild-type cancers could be revealed with regard to
miR-34a specific promotor methylation (Table 1). When
we separately analysed the serous histological subtype we
revealed that high grade cancers showed a significant
lower miR-34a(EXP) than the low grade serous cancers
(p = 0.004); (Table 1, Fig. 1d).
In accordance with the assumption that full methylation
of CpG islands in a promotor leads to gene silencing,
expression of miR-34a (miR-34a(EXP)) and methylation
status of its promotor (miR-34a(MET)) showed negative
correlation (rs = −0.254, p = 0.05); Fig. 2.
Survival analysis
As no data at all are available on clinical relevance of
miR-34a expression, we calculated an optimal cut-off for
both by stratifying patients of this training set into 2
groups according to their miR-34a expression, using
various cut-off points set arbitrarily between the 20th
and 80th percentile. Survival curves were calculated for
each of these cut-offs, and p values were calculated. The
optimal cut-off point for miR-34a expression with the
highest level of significance was the 20th percentile
which was used as discriminator for miR-34a positive
and negative expression status. Regarding miR-34a
methylation we used as threshold the presence or the
absence of methylation, however, we were not able to
find significant survival differences in our cohort with
regard to miR-34a promoter methylation.
Univariate survival analysis for miR-34a(EXP) at the
20th-percentile for PFS and OS shows that tumor speci-
mens with low miR-34a expression have significant
worse PFS (p = 0.037) and OS (p = 0.004) (Fig. 3a and b).
In the multivariate Cox regression model, including
the variables FIGO stage, grading, residual disease and
histological subtype, miR-34a(EXP) retained independent
prognostic power both for PFS (HR 0.549 (95 % CI
Fig. 1 miR-34a expression in different clinico-pathologic characteristics. a in grade 1, 2 and 3 ovarian cancers. b in type I and type II tumors (according
to the dualistic classification of Kurman et al.). c according to p53 mutational status. d) in low grade serous carcinomas (LGSC) and high grade serous
carcinomas (HGSC). P-value is calculated with non-parametric tests (Mann Whitney for between two variable and Kruskal Wallis test between three or
more variables. Y-axis represents the value of miR-34a expression as arbitrary unit normalized to TBP
Schmid et al. BMC Cancer  (2016) 16:102 Page 4 of 8
0.310–0.969), p = 0.039) and OS (HR 0.509 (95 % CI
0.293–0.883), p = 0.016) (Table 2).
Survival analysis was performed separately for the vari-
ous histological subtypes excluding the clear cell cancers
which were underrepresented. In serous cancers the
univariate approach showed a worse OS in case of
low miR-34a values (p = 0.016) but was not able to
demonstrate a significance difference in PFS (Fig. 3b–c).
This worse OS was confirmed in the multivariate setting
(HR 0.394 (95 % CI 0.178–0.873) p = 0.022, Table 2. In
mucinous cancers low expression of miR-34a in univariate
analysis showed a borderline worse PFS (p = 0.052) which
could not be confirmed in multivariate analysis.
In none of the analysed histological subtypes methyla-
tion of the miR-34a promoter was found to be of prognos-
tic relevance.
Discussion
Gene-silencing through promotor methylation is a unique
and reversible mechanism in the context of epigenetic
regulation of the genome in general. Accordingly, in many
human cancers promotor hypermethylation of tumor-
suppressor genes is detected. MiRNAs represent another
epigenetic machinery for controlling definitive gene ex-
pression in so far as translation of transcripted mRNA is
specifically abrogated via mRNA degradation after select-
ive binding by miRNAs.
We investigated the clinical impact of miR-34a as well
as the methylation status of its promotor in ovarian can-
cer. The degree of promotor hypermethylation was signifi-
cantly inversely associated with the expression of miR-34a
although the association found was not strong. The low
level of significance is probably due to the low number of
cancer with detectable methylation. Significant inverse as-
sociations between promotor methylation and the respect-
ive gene expression are not always given especially in
clinical data sets, as expression of genes often seems to be
only moderately affected by hypermethylation of the re-
spective promotor. However, our findings tempted us to
speculate that in ovarian cancers miR-34a-driven epigen-
etic regulation of gene translation is partially governed by
a second epigenetic mechanism, namely DNA methylation.
This is an excellent example that shows how epigenetic
regulation itself is controlled by epigenetics.
Univariate and multivariate survival analyses performed
in the whole cohort of patients revealed that tumoral
miR-34a expression below the 20 % percentile was associ-
ated with poor PFS and OS.
This is in agreement with the recently reported finding
that miR-34a is also a crucial suppressor of the cell cycle
rs= -0.254, p=0.05
Fig. 2 Correlation between miR-34a expression and miR-34a methylation. Graphic representation of the inverse linear correlation between miR-34a
expression and its promoter methylation. Y-axis represent miR-34a expression as arbitrary units normalized to TBP and X-axis represent methylation of
miR-34a as PMR value (percentage of methylated reference)
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promoting factor E2F3a, which was revealed to be a very
important regulator in EGFR-driven growth signaling in
ovarian cancer [16]. The epigenetic control by promotor
methylation of the miR-34a gene, has been shown to in-
crease E2F3a expression in vivo and highlights miR-34a
as a substantial regulator in ovarian cancer biology [14].
In this context, it has been previously shown that miR-
34a expression is directly inducible by p53 and putatively
involved in G1 arrest and apoptosis. Accordingly, it was
found that ovarian cancers with mutations leading to
p53 inactivation, were associated with significantly lower
levels of miR-34a(EXP) and higher levels of E2F3a [12].
Furthermore, it has been revealed that only an intact
p53/miR-34a axis is able to suppress L1CAM [13]. Ex-
pression of L1CAM has been found to correlate with poor
prognosis and metastasis in ovarian and endometrial car-
cinomas [17, 18]. L1CAM cleavage and its concomitant
release of the soluble molecule have been shown to pro-
mote migration, invasion and protection from apoptosis
of cancer cells. After all, the miR-34a regulated L1CAM
expression contributes to the invasive and metastatic
phenotype of serous ovarian carcinoma [19].
P53 wild-type directly transactivates miR-34a, and
may execute, at least partially, its function as a tumor-
suppressor via up-regulation of miR-34a. This is under-
scored by the biologically relevant connection between
the expression of miR-34a and the p53 functional status
in our cohort of patients. However, it appears that
p53 is not the only determining factor of miR-34a ex-
pression and miR-34a promotor methylation status
plays a significant role in miR-34a expression in ovar-
ian cancer cells.
Even though the p53 mutation-driven type II ovarian
cancers exhibit lower miR-34a expression and higher
methylation of the miR-34a promotor than do type I
cancers, no association between the methylation status
of miR-34a and p53 function could be revealed.
It is well known that restoration of functional p53 is
an attractive approach for gene therapy due to the large
number of p53 transcription targets, including miR-34a
[20]. However, first attempts at p53 gene therapy in
ovarian cancer patients failed to prove their therapeutic
efficiency in a randomized clinical phase 3 trial [21].
Possibly, miR-34a could be more attractive than p53 due
Fig. 3 Univariate survival analysis based on miR-34a expression. a-b PFS and OS in the entire cohort according to high and low miR-34a expression
level. c-d PFS and OS in serous cancers according to high and low miR-34a expression level. Cut off used for miR-34a expression: 20th percentile of the
entire cancer cohort (see results section for details). P-value calculated with log-rank test
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to its smaller molecular size, making it more prone for
viral or non-viral transfection.
Wei et al. [22] investigated the clinical importance of
miR-34a in gastric cancer specimens and revealed that
miR-34a is a valuable predictor of favorable prognosis.
miR-34a was shown in vitro to act as a tumor suppressor
inhibiting gastric cancer cell proliferation and invasion
via downregulation of MET. This also points out that
miR-34a has different targets to execute its function as
tumor suppressor.
In ovarian cancer another target of miR-34a is AXL,
a tyrosine kinase receptor with oncogenic properties. Re-
cently Li et al. [23] found in vitro that miR-34a suppresses
ovarian cancer proliferation and motility by targeting AXL.
A work from 2011 Vogt et al. [24] showed that miR-
34a and miR-34b/c are inactivated by CpG methylation.
They investigated promoter methylation in several
tumor types including ovarian cancers. From 13 ovarian
cancer samples analysed from ovarian cancer 8 (61.54 %)
showed methylation of the CpG).
Conclusion
The inverse correlations between miR-34a expression
and grading, p53 mutation status and dualistic tumor
type classification, together with its prognostic relevance
shown herein in multivariate survival analysis may under-
line the tumor-suppressive property of miR-34a in ovarian
cancer. Altogether, these findings underscore the rele-
vance of miR-34a in ovarian cancer cell biology with
special regard to its inhibitory effect on proliferation
and invasion.
The clinical impact shown in this training set needs to
be confirmed in a larger study population with regard to
the various histological and molecular-biological subtypes.
Beyond its prognostic relevance miR-34a could in fact
open new avenues in the development of innovative
treatment approaches modulating the expression of a
number of molecules decisively involved in the progres-
sion of ovarian cancer.
Ethics
The study was conducted in accordance with the princi-
ples of the Helsinki Declaration after approval by the local
ethics committee (Ethikkommission der Medizinischen
Universität Innsbruck, Innrain 43, A-6020 Innsbruck) for
both the case and control participants. Clinical, patho-
logical and follow-up data were stored in a database in ac-
cordance with hospital privacy rules. Tumor samples and
clinical data as well as control samples were collected after
obtaining written informed consent.
Table 2 Multivariate cox regression survival analysis
PFS OS
HR CI 95 % p value HR CI 95 % p value
miR-34a expressionc high 0.549 [0.31–0.969] 0.039a 0.509 [0.293–0.883] 0.016a
low 1
FIGO stage late 1.646 [0.7–3.871] 0.253 2.058 [0.895–4.727] 0.089
early 1
Age >62.3 1.69 [1.017–2.813] 0.043a 2.565 [1.571–4.189] <0.0001b
<62.3 1
Residual disease RD > 0 1.97 [1.057–3.674] 0.033a 2.565 [1.571–4.189] 0.001b
RD = 0 1
Hystology d 0.998 [0.773–1.288] 0.987 1.132 [0.886–1.446] 0.321
Serous cancers
PFS OS
HR CI 95 % p value HR CI 95 % p value
miR-34a expressionc high 0.509 [0.227–1.143] 0.102 0.389 [0.173–0.876] 0.022a
low 1
FIGO stage late 2.866 [0.77–10.662] 0.043 2.858 [0.748–10.915] 0.125
early 1
Age >62.3 2.304 [1.082–4.905] 0.032 2.925 [1.386–6.174] 0.005
<62.3 1
Residual disease RD > 0 1.194 [0.456–3.128] 0.718 1.080 [0.397–2.938] 0.879
RD = 0 1
asignificant at the 0.05 level (2-tailed). bsignificant at the 0.01 level (2-tailed). carbitrary units normalized to TBP, cut off = 20th centile (0.14)
dserous VS endometrioid VS mucinous VS clear cell
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